Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Bookmark and Share
Published: 31 May 2014
Views: 3012
Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

At a press conference at ASCO 2014, Prof Schlumberger talks about the results of the phase three SELECT trial, which was a multicentre, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131 l-refractory differentiated thyroid cancer.

Read the article for more.